Hotspan Research Library

Published research, cited and verifiable.

This page lists published, peer-reviewed research for each peptide in the Hotspan catalog, in alphabetical order by Hotspan product name. Every citation was retrieved from PubMed (U.S. National Library of Medicine) and can be verified through the PMID link given.

32Peptides covered
122PubMed citations
73Human studies
Every citation from PubMedPMID links to verifyHuman & preclinical dataAlphabetical by product

How to read this page

Each “Findings” summary reflects the conclusions stated in the study's published abstract, condensed and in some places quoted closely. Study type is noted for each entry; human clinical data are listed where available, followed by animal and laboratory studies. Many of the human trials used pharmaceutical-grade versions of a compound (e.g., afamelanotide, bremelanotide), sometimes with a different formulation or route than research material.

Research use only

All Hotspan products are sold strictly for laboratory research use only. They are not intended for human or veterinary use, and nothing in these research citations is a claim that any Hotspan product diagnoses, treats, cures or prevents any disease. Blend products (CJC-1295 + Ipamorelin, BPC-157 + TB-500, GLOW, KLOW) are covered under their component peptides.

AOD-9604

1Study type: Preclinical (animal / in vitro) study

Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. PMID: 11146367. doi:10.1159/000053183

Findings: The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic activity. In contrast to chronic treatment with intact hGH, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques. The results in the present study suggest that the analogue of the hGH lipolytic domain may have the potential to be developed into an orally usable and safe therapeutic agent for obesity.

https://pubmed.ncbi.nlm.nih.gov/11146367/
2Study type: Preclinical (animal / in vitro) study

Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. PMID: 11713213. doi:10.1210/endo.142.12.8522

Findings: The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.

https://pubmed.ncbi.nlm.nih.gov/11713213/
3Study type: Preclinical (animal / in vitro) study

Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-9. PMID: 11673763. doi:10.1038/sj.ijo.0801740

Findings: Both hGH and its C-terminal fragment reduce body weight gain, increase fat oxidation, and stimulate lipolysis in obese mice, yet AOD9604 does not interact with the hGH receptor. Thus, the concept of hGH behaving as a pro-hormone is further confirmed. This data shows that fragments of hGH can act in a manner novel to traditional hGH-stimulated pathways.

https://pubmed.ncbi.nlm.nih.gov/11673763/
4Study type: Preclinical (animal / in vitro) study

Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32. PMID: 26275694.

Findings: Mean gross morphological and histopathological scores were significantly higher in Group 1 than in Groups 2, 3, and 4, and the scores were significantly lower in Group 4 than in Groups 2 and 3. Intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone in the collagenase-induced knee OA rabbit model.

https://pubmed.ncbi.nlm.nih.gov/26275694/

ARA-290

1Study type: Human randomized controlled trial

Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-6. PMID: 23168581. doi:10.2119/molmed.2012.00332

Findings: The mean BPI and FAS scores improved significantly but equivalently in both patient groups. No change was observed in the IDS. ARA 290 appears to be safe in patients with sarcoidosis and can reduce neuropathic symptoms.

https://pubmed.ncbi.nlm.nih.gov/23168581/
2Study type: Human randomized controlled trial

Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19(1):334-45. PMID: 24136731. doi:10.2119/molmed.2013.00122

Findings: Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms. In addition to improved patient-reported symptom-based outcomes, ARA 290 administration was also associated with a significant increase in corneal small nerve fiber density, changes in cutaneous temperature sensitivity, and an increased exercise capacity as assessed by the 6-minute walk test. On the basis of these results and of prior studies, ARA 290 is a potential disease-modifying agent for treatment of sarcoidosis-associated SNFLD.

https://pubmed.ncbi.nlm.nih.gov/24136731/
3Study type: Human clinical trial

Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20(1):658-66. PMID: 25387363. doi:10.2119/molmed.2014.00215

Findings: Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation.

https://pubmed.ncbi.nlm.nih.gov/25387363/
4Study type: Human randomized controlled trial

Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. PMID: 28475703. doi:10.1167/iovs.16-21291

Findings: Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect. The relationships between CNFA and other clinical measures of disease support its use as a surrogate endpoint to assess potential disease modifying therapies for neuropathy.

https://pubmed.ncbi.nlm.nih.gov/28475703/

BPC-157

1Study type: Preclinical (animal / in vitro) study

Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PMID: 14554208. doi:10.1016/S0736-0266(03)00110-4

Findings: In rat Achilles tendon transection, BPC 157 improved functional, biomechanical and histological healing versus controls. In cultured tendon fibroblasts it promoted outgrowth and counteracted the growth-inhibiting aldehyde 4-hydroxynonenal, supporting a direct pro-healing effect on tendon cells.

https://pubmed.ncbi.nlm.nih.gov/14554208/
2Study type: Human retrospective case series

Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.

Findings: Of the 16 patients, 12 had received only BPC 157 as an intra-articular injection. This small study suggests that intra-articular injection of BPC-157 helps with multiple types of knee pain.

https://pubmed.ncbi.nlm.nih.gov/34324435/
3Study type: Review

Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020;26(25):2971-2981. PMID: 32445447. doi:10.2174/1381612826666200523180301

Findings: Review of BPC 157's cytoprotective actions in the gut. The authors describe evidence that BPC 157 stabilizes intestinal permeability and counteracts NSAID-induced gastrointestinal injury, proposing it as a candidate for protecting GI safety against NSAID cytotoxicity and leaky-gut-type damage.

https://pubmed.ncbi.nlm.nih.gov/32445447/
4Study type: Review

Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654. doi:10.3389/fphar.2021.627533

Findings: Review of BPC 157 in wound healing across preclinical models. BPC 157 rapidly increased expression of healing-related genes in rat skin wounds, and the authors describe healing effects across gastrointestinal tract, tendon, ligament, muscle, bone, nerve, cornea and blood vessels, including bypassing of occluded vessels in ischemia/reperfusion.

https://pubmed.ncbi.nlm.nih.gov/34267654/
5Study type: Review

Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID: 40756949. doi:10.1177/15563316251355551

Findings: Conclusion: This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety. We recommend that clinicians counsel athletes to understand their organizations' rules to remain compliant with medication/supplement safety and testing standards.

https://pubmed.ncbi.nlm.nih.gov/40756949/

CJC-1295 (No DAC / Mod GRF 1-29)

1Study type: Human clinical study

Barron JL, Coy DH, Millar RP. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides. 1985;6(3):575-7. PMID: 2866496. doi:10.1016/0196-9781(85)90124-x

Findings: Neither analog affected blood levels of PRL, TSH, LH, FSH, ACTH, insulin, glucagon, glucose, cortisol, free thyroxine, and free triiodothyronine. No side effects were noted other than transient flushing with the highest dose administered. The findings demonstrate GHRH(1-29)-NH2 and its D-Ala2 analog are potent stimulators of GH release and have potential application in clinical medicine.

https://pubmed.ncbi.nlm.nih.gov/2866496/
2Study type: Human clinical trial

Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID: 9005976. doi:10.1016/s0026-0495(97)90174-8

Findings: In healthy elderly men, nightly GHRH(1-29) injections were less effective than multiple daily doses at raising GH/IGF-I, but the authors report GHRH treatment may increase muscle strength and shifted muscle bioenergetics toward reduced anaerobic demand during exercise, supporting further work on optimized regimens.

https://pubmed.ncbi.nlm.nih.gov/9005976/
3Study type: Human clinical study

Ross RJ, Rodda C, Tsagarakis S, Davies PS, Grossman A, Rees LH, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987;1(8523):5-8. PMID: 2879138. doi:10.1016/s0140-6736(87)90699-4

Findings: Although anti-GHRH antibodies developed in 14 patients, these did not seem to have adverse effects on either growth or the GH responses to GHRH. GHRH (1-29) NH2 therapy is an alternative to conventional hGH in the treatment of some GH-deficient children. Ideal dose regimens need to be established.

https://pubmed.ncbi.nlm.nih.gov/2879138/

CJC-1295 with DAC

1Study type: Human randomized controlled trial

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. doi:10.1210/jc.2005-1536

Findings: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.

https://pubmed.ncbi.nlm.nih.gov/16352683/
2Study type: Preclinical (animal / in vitro) study

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. PMID: 16822960. doi:10.1152/ajpendo.00201.2006

Findings: CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images. These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.

https://pubmed.ncbi.nlm.nih.gov/16822960/
3Study type: Human clinical trial

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 17018654. doi:10.1210/jc.2006-1702

Findings: CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability.

https://pubmed.ncbi.nlm.nih.gov/17018654/

DSIP

1Study type: Human clinical trial

Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-9. PMID: 3622582. doi:10.1159/000116143

Findings: Efficiency of night sleep and daytime rest reached the levels of normal controls. Alertness and performance at daytime increased significantly. The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.

https://pubmed.ncbi.nlm.nih.gov/3622582/
2Study type: Human clinical trial

Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(9):913-7. PMID: 7028502. doi:10.1007/BF01971753

Findings: The results were: longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects though the sleep enhancing capacity was seen for up to 6 h of night sleep. Sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated. The study corroborates the findings of previous investigations in healthy subjects and shows that DSIP has a normalizing influence on human sleep regulation.

https://pubmed.ncbi.nlm.nih.gov/7028502/
3Study type: Human clinical study (open)

Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. PMID: 6548970. doi:10.1159/000115716

Findings: The anamnestic (baseline) values were statistically compared with the katamnestic control period. DSIP lowered significantly the pain levels of 6 out of 7 patients after intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h. Remarkably, a simultaneous significant reduction of the concomitantly occurring depressive states was observed.

https://pubmed.ncbi.nlm.nih.gov/6548970/

Epithalon

1Study type: Preclinical (animal / in vitro) study

Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PMID: 12937682. doi:10.1023/a:1025493705728

Findings: Addition of Epithalon peptide in telomerase-negative human fetal fibroblast culture induced expression of the catalytical subunit, enzymatic activity of telomerase, and telomere elongation, which can be due to reactivation of telomerase gene in somatic cells and indicates the possibility of prolonging life span of a cell population and of the whole organism.

https://pubmed.ncbi.nlm.nih.gov/12937682/
2Study type: Preclinical (animal / in vitro) study

Anisimov VN, Khavinson VKh, Alimova IN, Semchenko AV, Yashin AI. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bull Exp Biol Med. 2002;134(2):187-90. PMID: 12459848. doi:10.1023/a:1021104819170

Findings: Epithalon 3.7-fold increased the number of mice without breast tumors (p<0.05), while the number of animals with 6 or more breast tumors decreased by 3 times (p<0.05). Epithalon prolonged the lifetime of mice with breast tumors by 1.4 times (p<0.05). These results indicate that Epithalon possesses geroprotective activity and inhibits breast carcinogenesis in transgenic mice, which is probably related to suppression of HER-2/neu expression.

https://pubmed.ncbi.nlm.nih.gov/12459848/
3Study type: Preclinical (animal / in vitro) study

Goncharova ND, Khavinson BK, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bull Exp Biol Med. 2001;131(4):394-6. PMID: 11550036. doi:10.1023/a:1017928925177

Findings: The effect of Epithalon on melatonin and cortisol secretion in female rhesus monkeys of various ages was evaluated by enzyme immunoassay. Epithalon stimulated evening melatonin production and normalized circadian rhythms of cortisol production in old monkeys.

https://pubmed.ncbi.nlm.nih.gov/11550036/
4Study type: Preclinical (animal / in vitro) study

Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID: 40908429. doi:10.1007/s10522-025-10315-x

Findings: In cancer cells, significant telomere length extension also occurred through ALT (Alternative Lengthening of Telomeres) activation. Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells. Our data suggests that epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of hTERT mRNA expression and telomerase enzyme activity.

https://pubmed.ncbi.nlm.nih.gov/40908429/

GHK-Cu

1Study type: Preclinical (animal / in vitro) study

Bian Y, Deng M, Liu J, Li J, Zhang Q, Wang Z, et al. The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024;75:103237. PMID: 38879894. doi:10.1016/j.redox.2024.103237

Findings: These effects were partly related to the inhibition of the CS-induced oxidative stress in AM induced by GHK-Cu. Thus, our results suggest that GHK-Cu acts as a potential drug by attenuating alveolar macrophage oxidative stress. This, in turn, attenuates the progression of pulmonary inflammation and fibrosis, which provides a reference for the treatment of silicosis.

https://pubmed.ncbi.nlm.nih.gov/38879894/
2Study type: Preclinical (animal / in vitro) study

Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. PMID: 35936787. doi:10.3389/fmolb.2022.925700

Findings: Furthermore, administration of GHK-Cu reversed the increase in NF-κB expression induced by CS and increased the Nrf2 level, as an antioxidant defense component, in mice with chronic CS exposure. In CSE-exposed human alveolar epithelial A549 cells, GHK-Cu also inhibited oxidative stress by suppressing MDA levels and restoring T-AOC and GSH levels, which were modulated by upregulating Nrf2 expression. Conclusion: GHK-Cu treatment attenuated CS-induced emphysema by anti-inflammation by downregulating NF-κB and antioxidation via upregulation of the Nrf2/Keap1 in lung tissues.

https://pubmed.ncbi.nlm.nih.gov/35936787/
3Study type: Preclinical (animal / in vitro) study

Deng M, Zhang Q, Yan L, Bian Y, Li R, Gao J, et al. Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle. 2023;14(3):1365-1380. PMID: 36905132. doi:10.1002/jcsm.13213

Findings: Plasma glycyl-l-histidyl-l-lysine level in patients with chronic obstructive pulmonary disease was significantly decreased and was significantly associated with skeletal muscle mass. Exogenous administration of glycyl-l-histidyl-l-lysine-Cu2+ could protect against cigarette smoking-induced skeletal muscle dysfunction via sirtuin 1.

https://pubmed.ncbi.nlm.nih.gov/36905132/
4Study type: Review

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7). PMID: 29986520. doi:10.3390/ijms19071987

Findings: GHK's ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining. GHK has also been found to possess powerful cell protective actions, such as multiple anti-cancer activities and anti-inflammatory actions, lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts, suppression of molecules thought to accelerate the diseases of aging such as NFκB, anti-anxiety, anti-pain and anti-aggression activities, DNA repair, and activation of cell cleansing via the proteasome system. Recent genetic data may explain such diverse protective and healing actions of one molecule, revealing multiple biochemical pathways regulated by GHK.

https://pubmed.ncbi.nlm.nih.gov/29986520/

Glutathione

1Study type: Human randomized controlled trial

Richie JP, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-63. PMID: 24791752. doi:10.1007/s00394-014-0706-z

Findings: GSH levels in blood increased after 1, 3 and 6 months versus baseline at both doses. These findings show, for the first time, that daily consumption of GSH supplements was effective at increasing body compartment stores of GSH.

https://pubmed.ncbi.nlm.nih.gov/24791752/
2Study type: Human randomized controlled trial

Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97-102. PMID: 20524875. doi:10.3109/09546631003801619

Findings: Oral glutathione administration results in a lightening of skin color in a small number of subjects. However, long-term safety has not been established and warrants more extensive clinical trials.

https://pubmed.ncbi.nlm.nih.gov/20524875/
3Study type: Human randomized controlled trial

Visca A, Bishop CT, Hilton S, Hudson VM. Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 2015;60(6):802-10. PMID: 25633497. doi:10.1097/MPG.0000000000000738

Findings: The GSH treatment group gained an average of 0.67 standard deviation (SD) in weight-for-age-and sex z score (wfaszs), (19.1 weight percentile points) during the course of 6 months, with no adverse effects (vs placebo with an increase of 0.1 SD in wfaszs [2.1 weight percentile points], P < 0.0001). Oral reduced L-GSH significantly improves measures of growth status and gut inflammation in CF.

https://pubmed.ncbi.nlm.nih.gov/25633497/
4Study type: Human randomized controlled trial

Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009;24(7):979-83. PMID: 19230029. doi:10.1002/mds.22401

Findings: Over the 4 weeks of study medication administration, UPDRS ADL + motor scores improved by a mean of 2.8 units more in the glutathione group (P = 0.32), and over the subsequent 8 weeks worsened by a mean of 3.5 units more in the glutathione group (P = 0.54). Glutathione was well tolerated and no safety concerns were identified. Preliminary efficacy data suggest the possibility of a mild symptomatic effect, but this remains to be evaluated in a larger study.

https://pubmed.ncbi.nlm.nih.gov/19230029/

Gonadorelin (GnRH)

1Study type: Human clinical trial

Gong C, Liu Y, Qin M, Wu D, Wang X. Pulsatile GnRH Is Superior to hCG in Therapeutic Efficacy in Adolescent Boys With Hypogonadotropic Hypogonadodism. J Clin Endocrinol Metab. 2015;100(7):2793-9. PMID: 25978110. doi:10.1210/jc.2015-1343

Findings: Boys with HH may be effectively treated with GnRH. We suggested that GnRH exhibits higher efficacy in treating adolescent boys with HH than hCG.

https://pubmed.ncbi.nlm.nih.gov/25978110/
2Study type: Human randomized controlled trial

Dubourdieu S, Fréour T, Dessolle L, Barrière P. Prospective, randomized comparison between pulsatile GnRH therapy and combined gonadotropin (FSH+LH) treatment for ovulation induction in women with hypothalamic amenorrhea and underlying polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;168(1):45-8. PMID: 23298894. doi:10.1016/j.ejogrb.2012.12.016

Findings: HA/PCOS is a specific subgroup of infertile women. Pulsatile GnRH therapy is an effective and safe method of ovulation induction that can be used successfully in these patients.

https://pubmed.ncbi.nlm.nih.gov/23298894/
3Study type: Human clinical trial

Tan SL, Farhi J, Homburg R, Jacobs HS. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. Obstet Gynecol. 1996;88(2):221-6. PMID: 8692506. doi:10.1016/0029-7844(96)00190-1

Findings: The use of subcutaneous pulsatile GnRH alone and in combination with clomiphene citrate or gonadotropins for induction of ovulation in clomiphene-resistant PCOS in a stepwise approach produces a high cumulative conception rate associated with a low rate of multiple pregnancy and ovarian hyperstimulation syndrome.

https://pubmed.ncbi.nlm.nih.gov/8692506/
4Study type: Human clinical study

Blunt SM, Butt WR. Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism. Acta Endocrinol Suppl (Copenh). 1988;288:58-65. PMID: 3138867.

Findings: The median time to conception was 3 ovulatory cycles. Although there were no serious complications with iv or sc therapy, the iv route is now reserved for those patients unresponsive to sc treatment as the sc route is potentially safer and more acceptable to the patient. In correctly selected patients pulsatile GnRH is a highly effective and safe new treatment for the induction of ovulation.

https://pubmed.ncbi.nlm.nih.gov/3138867/

Hexarelin

1Study type: Human clinical trial

Broglio F, Guarracino F, Benso A, Gottero C, Prodam F, Granata R, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol. 2002;448(2-3):193-200. PMID: 12144941. doi:10.1016/s0014-2999(02)01934-9

Findings: Hexarelin induced a slight increase in GH levels which was similar to that after GHRH but far lower (P < 0.01) than that after rhGH. Thus, in patients with coronary artery disease undergoing by-pass surgery, the acute administration of hexarelin clearly improves cardiac performance without any relevant variation in systemic vascular resistance. The cardiotropic effect of hexarelin is not shared by GHRH or by rhGH, indicating that it is not mediated by the increase in circulating GH levels but more likely reflects activation of specific cardiovascular GH secretagogue receptors.

https://pubmed.ncbi.nlm.nih.gov/12144941/
2Study type: Preclinical (animal / in vitro) study

McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiol Rep. 2018;6(9):e13699. PMID: 29756411. doi:10.14814/phy2.13699

Findings: Furthermore, heart rate variability analysis demonstrated that HEX treatment shifted the balance of autonomic nervous activity toward a parasympathetic predominance and sympathetic downregulation. This was combined with a HEX-dependent decrease in troponin-I, IL-1β and TNF-α levels suggestive of amelioration of cardiomyocyte injury. These results demonstrate that GHS may preserve ventricular function, reduce inflammation and favorably remodel the process of fibrotic healing in a mouse model of MI and hold the potential for translational application to patients suffering from MI.

https://pubmed.ncbi.nlm.nih.gov/29756411/
3Study type: Preclinical (animal / in vitro) study

McDonald H, Peart J, Kurniawan ND, Galloway G, Royce SG, Samuel CS, et al. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomed Pharmacother. 2020;127:110165. PMID: 32403043. doi:10.1016/j.biopha.2020.110165

Findings: HEX treatment shifted the ANS balance towards a parasympathetic predominance; combined with a significant decrease in cardiac troponin-I and TNF-α levels, these findings were suggestive of an anti-inflammatory action on the myocardium mediated via HEX. In this model of IR, HEX appeared to rebalance the deregulated ANS and activate vagal anti-inflammatory pathways to prevent adverse remodelling and LV dysfunction. There are limited interventions focusing on IRI that have been successful in improving clinical outcome in acute myocardial infarction (AMI) patients, this study provides compelling evidence towards the translational potential of HEX where all others have largely failed.

https://pubmed.ncbi.nlm.nih.gov/32403043/
4Study type: Preclinical (animal / in vitro) study

Jiang B, Wang M, Li X, Ren P, Li G, Wang Y, et al. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvasc Res. 2022;140:104280. PMID: 34856183. doi:10.1016/j.mvr.2021.104280

Findings: Furthermore, hexarelin inhibited inflammatory cell infiltration, NLRP3 inflammasome activation and IL-18 production. Particularly, hexarelin suppressed NF-κB signaling pathway which is a key initiator of inflammatory response. These results demonstrated that hexarelin attenuated AAA development by inhibiting SMC phenotype switch and NF-κB signaling mediated inflammatory response.

https://pubmed.ncbi.nlm.nih.gov/34856183/

Ipamorelin

1Study type: Preclinical (animal / in vitro) study

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822. doi:10.1530/eje.0.1390552

Findings: This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

https://pubmed.ncbi.nlm.nih.gov/9849822/
2Study type: Preclinical (animal / in vitro) study

Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343. doi:10.1054/ghir.1999.9998

Findings: The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin, but unchanged after GHRH. The pituitary GH content was unchanged by ipamorelin treatment. Whether ipamorelin or other GH secretagogues may have a place in the treatment of children with growth retardation requires demonstration in future clinical studies.

https://pubmed.ncbi.nlm.nih.gov/10373343/
3Study type: Preclinical (animal / in vitro) study

Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-77. PMID: 10828840. doi:10.1677/joe.0.1650569

Findings: Ash weight was increased by all treatments, but the mineral concentration was unchanged. We conclude that treatment of adult female rats with the GHSs ipamorelin and GHRP-6 increases BMC as measured by DXA in vivo. The results of in vitro measurements using pQCT and Archimedes' principle, in addition to ash weight determinations, show that the increases in cortical and total BMC were due to an increased growth of the bones with increased bone dimensions, whereas the volumetric BMD was unchanged.

https://pubmed.ncbi.nlm.nih.gov/10828840/

Kisspeptin-10

1Study type: Human randomized controlled trial

Yeung AC, Phylactou M, Koysombat K, Tsoutsouki J, Nyunt SW, Young M, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PMID: 42549827. doi:10.1093/ejendo/lvag134

Findings: We demonstrate that chronic subcutaneous kisspeptin administration sustains gonadotropin and testosterone secretion in healthy men for 12 days. These data can inform development of chronic kisspeptin administration protocols for the treatment of reproductive disorders.

https://pubmed.ncbi.nlm.nih.gov/42549827/
2Study type: Human clinical study

Ullah H, Nabi G, Zubair H, Ullah R, Shahab M. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia. 2019;51(4):e13219. PMID: 30590872. doi:10.1111/and.13219

Findings: Analysis of plasma LH by ELISA showed a significant (p < 0.05) increase after kisspeptin-10 administration in all groups, whereas plasma testosterone concentration was significantly elevated (p < 0.05) after kisspeptin-10 injection only in the adult men group. Present results suggest that in men, central hypothalamic-pituitary axis remains active and shows responsiveness to kisspeptin stimulation across life. However, Leydig cell responsiveness to kisspeptin-induced LH decreases with age in men.

https://pubmed.ncbi.nlm.nih.gov/30590872/
3Study type: Human clinical study

Chan YM, Lippincott MF, Butler JP, Sidhoum VF, Li CX, Plummer L, et al. Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2014;99(12):E2762-71. PMID: 25226293. doi:10.1210/jc.2014-2233

Findings: The functional capacity of the GnRH neuronal network in IHH patients is impaired, as evidenced by their inability to respond to the same dose of kisspeptin that effects a robust GnRH-induced LH response in healthy men and luteal-phase women. This impairment is observed across a range of genotypes, suggesting that it reflects a fundamental property of GnRH neuronal networks that have not been properly engaged during pubertal development. In contrast, a patient who had experienced reversal of his hypogonadotropism responded to exogenous kisspeptin.

https://pubmed.ncbi.nlm.nih.gov/25226293/

KPV

1Study type: Preclinical (animal / in vitro) study

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177. doi:10.1053/j.gastro.2007.10.026

Findings: Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion. This study indicates tht KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.

https://pubmed.ncbi.nlm.nih.gov/18061177/
2Study type: Preclinical (animal / in vitro) study

Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. PMID: 18092346. doi:10.1002/ibd.20334

Findings: The melanocortin-derived tripeptide KPV showed significant anti-inflammatory effects in 2 murine models of colitis. These effects seem to be at least partially independent of MC1R signaling. In conclusion, our data suggest KPV as an interesting therapeutic option for the treatment of IBD.

https://pubmed.ncbi.nlm.nih.gov/18092346/
3Study type: Preclinical (animal / in vitro) study

Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741. doi:10.1016/j.ymthe.2016.11.020

Findings: Intriguingly, we found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation. Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system. These results collectively demonstrate that our HA-KPV-NP/hydrogel system has the capacity to release HA-KPV-NPs in the colonic lumen and that these NPs subsequently penetrate into colitis tissues and enable KPV to be internalized into target cells, thereby alleviating UC.

https://pubmed.ncbi.nlm.nih.gov/28143741/
4Study type: Preclinical (animal / in vitro) study

Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805.

Findings: KPV and γMSH respectively suppress NFκB signalling in airway epithelium by: i) inhibition of p65RelA nuclear import and, ii) epithelial MC3R activation. Melanocortin peptides therefore provide a robust mechanism for targeting airway inflammation in lung disease.

https://pubmed.ncbi.nlm.nih.gov/22837805/

Melanotan 1 (Afamelanotide)

1Study type: Human randomized controlled trial

Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48-59. PMID: 26132941. doi:10.1056/NEJMoa1411481

Findings: Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria. (Funded by Clinuvel Pharmaceuticals and others; ClinicalTrials.gov numbers, NCT01605136 and NCT00979745.).

https://pubmed.ncbi.nlm.nih.gov/26132941/
2Study type: Human randomized controlled trial

Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42-50. PMID: 25230094. doi:10.1001/jamadermatol.2014.1875

Findings: A combination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB-UV-B monotherapy. The response was more noticeable in patients with SPTs IV to VI.

https://pubmed.ncbi.nlm.nih.gov/25230094/
3Study type: Review

Minder EI. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin Investig Drugs. 2010;19(12):1591-602. PMID: 21073357. doi:10.1517/13543784.2010.535515

Findings: The different trials of afamelanotide in PP and their most recent results are discussed. Although early, results of the first trials of afamelanotide for PP are promising and the risk-safety profile appears favorable today. We expect afamelanotide and analogs thereof to be a prospective therapeutic tool in light-related skin diseases, and in future this drug class might prove effectiveness in other medical conditions.

https://pubmed.ncbi.nlm.nih.gov/21073357/
4Study type: Human clinical trial

Stanislaus V, Kam A, Murphy L, Wolgen P, Walker G, Bilbao P, et al. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial. BMC Neurol. 2023;23(1):281. PMID: 37496004. doi:10.1186/s12883-023-03338-9

Findings: Afamelanotide was well tolerated and safe in our small sample of AIS patients. It also appears to be associated with good recovery and radiological improvement of salvageable tissue which needs to be tested in randomized studies.

https://pubmed.ncbi.nlm.nih.gov/37496004/

Melanotan 2

1Study type: Human clinical trial

Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-9. PMID: 11035391. doi:10.1038/sj.ijir.3900582

Findings: We conclude that Melanotan II is a potent initiator of penile erection in men with erectile dysfunction. Our findings warrant further investigation of melanocortin agonists and antagonists on penile erection. International Journal of Impotence Research (2000) 12, Suppl 4, S74-S79.

https://pubmed.ncbi.nlm.nih.gov/11035391/
2Study type: Preclinical (animal / in vitro) study

Banno R, Arima H, Sato I, Hayashi M, Goto M, Sugimura Y, et al. The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats. Peptides. 2004;25(8):1279-86. PMID: 15350695. doi:10.1016/j.peptides.2004.05.007

Findings: MTII group showed more sensitivity to insulin compared with that allowed to eat ad libitum or pair-fed group in insulin tolerance tests on day 9. MTII group also showed significantly lower glucose values than ad libitum group in glucose tolerance tests on days 11 and 23. Thus, MTII increased insulin sensitivity and improved glucose tolerance in OLETF rats.

https://pubmed.ncbi.nlm.nih.gov/15350695/
3Study type: Preclinical (animal / in vitro) study

Paiva L, Sabatier N, Leng G, Ludwig M. Effect of Melanotan-II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats. J Neuroendocrinol. 2017;29(2). PMID: 28009464. doi:10.1111/jne.12454

Findings: Our data suggest that, after i.v., but not intranasal, administration of MT-II, the activity of magnocellular neurones of the SON is increased. Because previous studies showed that SON oxytocin neurones are inhibited in response to direct application of melanocortin agonists, the actions of i.v. MT-II are likely to be mediated at least partly indirectly, possibly by activation of inputs from the caudal brainstem, where MT-II also increased Fos expression.

https://pubmed.ncbi.nlm.nih.gov/28009464/

MOTS-c

1Study type: Preclinical (animal / in vitro) study

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PMID: 25738459. doi:10.1016/j.cmet.2015.02.009

Findings: Its primary target organ appears to be the skeletal muscle, and its cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation. MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. These results suggest that mitochondria may actively regulate metabolic homeostasis at the cellular and organismal level via peptides encoded within their genome.

https://pubmed.ncbi.nlm.nih.gov/25738459/
2Study type: Preclinical (animal / in vitro) study

Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109. doi:10.1038/s41467-020-20790-0

Findings: We provide evidence that late-life (23.5 mo.) initiated intermittent MOTS-c treatment (3x/week) can increase physical capacity and healthspan in mice. In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation. Our data indicate that aging is regulated by genes encoded in both of our co-evolved mitochondrial and nuclear genomes.

https://pubmed.ncbi.nlm.nih.gov/33473109/
3Study type: Preclinical (animal / in vitro) study

Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022;175:105987. PMID: 34798268. doi:10.1016/j.phrs.2021.105987

Findings: Similar to a previous study, MOTS-c also could activate insulin sensitivity in the skeletal muscle of GDM mice and elevate glucose uptake in vitro. In addition, we found that MOTS-c protects pancreatic β-cell from STZ-mediated injury. Taken together, our findings demonstrate that MOTS-c could be a promising strategy for the treatment of GDM.

https://pubmed.ncbi.nlm.nih.gov/34798268/
4Study type: Preclinical (animal / in vitro) study

Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PMID: 33554779. doi:10.1152/ajpendo.00275.2020

Findings: Further upstream, MOTS-c increases CK2 activity, which leads to PTEN inhibition. These results suggest that through inhibition of myostatin, MOTS-c could be a potential therapy for insulin resistance-induced skeletal muscle atrophy as well as other muscle wasting phenotypes including sarcopenia.NEW & NOTEWORTHY MOTS-c, a mitochondrial-derived peptide reduces high-fat-diet-induced muscle atrophy signaling by reducing myostatin expression. The CK2-PTEN-mTORC2-AKT-FOXO1 pathways play key roles in MOTS-c action on myostatin expression.

https://pubmed.ncbi.nlm.nih.gov/33554779/

NAD+

1Study type: Human randomized controlled trial

Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478. doi:10.1038/s41467-018-03421-7

Findings: In a 2 x 6-week randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults, nicotinamide riboside was well tolerated and effectively raised NAD+ levels. Exploratory analyses suggested it may lower blood pressure and arterial stiffness in people with elevated baseline blood pressure.

https://pubmed.ncbi.nlm.nih.gov/29599478/
2Study type: Human randomized controlled trial

Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6. PMID: 31412242. doi:10.1016/j.celrep.2019.07.043

Findings: Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics. NR also depressed levels of circulating inflammatory cytokines. Our data establish that oral NR is available to aged human muscle and identify anti-inflammatory effects of NR.

https://pubmed.ncbi.nlm.nih.gov/31412242/
3Study type: Human randomized controlled trial

Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596. doi:10.1126/science.abe9985

Findings: Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment. NMN supplementation up-regulated the expression of platelet-derived growth factor receptor β and other genes related to muscle remodeling. These results demonstrate that NMN increases muscle insulin sensitivity, insulin signaling, and remodeling in women with prediabetes who are overweight or obese (clinicaltrial.gov NCT03151239).

https://pubmed.ncbi.nlm.nih.gov/33888596/
4Study type: Human randomized controlled trial

Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. PMID: 36482258. doi:10.1007/s11357-022-00705-1

Findings: NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily. Clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake. This trial was registered with ClinicalTrials.gov, NCT04823260, and Clinical Trial Registry - India, CTRI/2021/03/032421.

https://pubmed.ncbi.nlm.nih.gov/36482258/
5Study type: Human randomized controlled trial

McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15(1):5046. PMID: 38871717. doi:10.1038/s41467-024-49092-5

Findings: Among participants who took at least 75% of study pills, compared to placebo, NR improved 6-min walk by 31.0 meters and NR + resveratrol improved 6-min walk by 26.9 meters. In this work, NR meaningfully improved 6-min walk, and resveratrol did not add benefit to NR alone in PAD. A larger clinical trial to confirm these findings is needed.

https://pubmed.ncbi.nlm.nih.gov/38871717/

Oxytocin

1Study type: Human clinical trial

Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-6. PMID: 15931222. doi:10.1038/nature03701

Findings: We also show that the effect of oxytocin on trust is not due to a general increase in the readiness to bear risks. On the contrary, oxytocin specifically affects an individual's willingness to accept social risks arising through interpersonal interactions. These results concur with animal research suggesting an essential role for oxytocin as a biological basis of prosocial approach behaviour.

https://pubmed.ncbi.nlm.nih.gov/15931222/
2Study type: Human randomized controlled trial

Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003;54(12):1389-98. PMID: 14675803. doi:10.1016/s0006-3223(03)00465-7

Findings: Oxytocin seems to enhance the buffering effect of social support on stress responsiveness. These results concur with data from animal research suggesting an important role of oxytocin as an underlying biological mechanism for stress-protective effects of positive social interactions.

https://pubmed.ncbi.nlm.nih.gov/14675803/
3Study type: Human randomized controlled trial

Domes G, Sibold M, Schulze L, Lischke A, Herpertz SC, Heinrichs M. Intranasal oxytocin increases covert attention to positive social cues. Psychol Med. 2013;43(8):1747-53. PMID: 23146328. doi:10.1017/S0033291712002565

Findings: Reaction times (RTs) in the dot-probe paradigm revealed a pronounced shift of attention towards happy facial expressions presented for 100 ms after OT administration, whereas there were no OT-induced effects for longer presentation times (500 ms). The results suggest that OT increased covert attention to happy faces, thereby supporting the hypothesis that OT modulates early attentional processes that might promote prosocial behavior.

https://pubmed.ncbi.nlm.nih.gov/23146328/

PT-141 (Bremelanotide)

1Study type: Human open-label extension (phase 3)

Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599847. doi:10.1097/AOG.0000000000003514

Findings: In the 52-week open-label extension of the RECONNECT phase 3 trials, no new safety signals were observed and premenopausal women treated with bremelanotide showed sustained improvements in hypoactive sexual desire disorder symptoms (desire and related distress).

https://pubmed.ncbi.nlm.nih.gov/31599847/
2Study type: Human randomized controlled trial

Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022;31(3):391-400. PMID: 35230162. doi:10.1089/jwh.2021.0225

Findings: Patients treated with bremelanotide experienced decreased distress compared with those in the placebo group at levels of statistical significance (p < 0.05) regardless of hormonal contraceptive use. Statistically significant improvements were observed in the presence or absence of decreased arousal, and regardless of HSDD duration. Conclusions: Bremelanotide was associated with statistically significant improvements in sexual desire and reduced distress across several prespecified subgroups, with few exceptions.

https://pubmed.ncbi.nlm.nih.gov/35230162/
3Study type: Human randomized controlled trial

Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. PMID: 35147466. doi:10.1089/jwh.2021.0191

Findings: Conclusions: The AEs associated with bremelanotide are mostly mild to moderate. Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Clinical Trial Registration number: NCT02333071 [Study 301] and NCT02338960 [Study 302].

https://pubmed.ncbi.nlm.nih.gov/35147466/

Selank

1Study type: Human clinical trial

Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. PMID: 25176261.

Findings: Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.

https://pubmed.ncbi.nlm.nih.gov/25176261/
2Study type: Human randomized controlled trial

Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.

Findings: The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.

https://pubmed.ncbi.nlm.nih.gov/18454096/
3Study type: Preclinical (animal / in vitro) study

Semenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Experimental optimization of learning and memory processes by selank]. Eksp Klin Farmakol. 2010;73(8):2-5. PMID: 20919548.

Findings: It was established that selank induces an increase in memory trace stability during 30 days. These findings provide direct evidence that selank, when injected during consolidation phase, can enhance memory storage processes. Nootrope activity of the selank is probably caused by its obvious effect on the level of serotonin and its metabolite in the brain.

https://pubmed.ncbi.nlm.nih.gov/20919548/
4Study type: Preclinical (animal / in vitro) study

Kolik LG, Nadorova AV, Seredenin SB. Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice. Bull Exp Biol Med. 2016;162(1):56-59. PMID: 27878720. doi:10.1007/s10517-016-3544-6

Findings: Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg intraperitoneally) hyperlocomotion, in contrast to σ1-receptors agonist Afobazole (1.0 mg/kg, intraperitoneally) that did not inhibit ethanol-induced behavioral stimulation. Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation. These findings suggest that Selank can modulate the motivational effects of ethanol.

https://pubmed.ncbi.nlm.nih.gov/27878720/

Semax

1Study type: Preclinical (animal) study

Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-6. PMID: 16635254. doi:10.1111/j.1471-4159.2006.03658.x

Findings: Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain, but not in the cerebellum. These results point to the presence of specific binding sites for Semax in the rat basal forebrain. In addition, these findings indicate that the cognitive effects exerted by Semax might be associated, at least in part, with increased BDNF protein levels in this brain region.

https://pubmed.ncbi.nlm.nih.gov/16635254/
2Study type: Preclinical (animal / in vitro) study

Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-9. PMID: 19633950. doi:10.1007/s10571-009-9432-0

Findings: Semax enhanced the transcription of Bdnf, TrkC, and TrkA 3 h after occlusion, Nt-3 and Ngf 24 h after occlusion, and Ngf 72 h after occlusion. PGP enhanced the transcription of Bdnf and TrkC 3 h after pMCAO and Ngf, TrkB, TrkC, and TrkA 24 h after pMCAO. The analysis of the transcription alterations under PGP and Semax treatment in the cortex of rats without surgery, sham-operated rats and rats subjected to pMCAO revealed that Semax selectively affected the transcription of neurotrophins and their receptors in the ischemic rat cortex, whereas the influence of PGP was mainly unspecific.

https://pubmed.ncbi.nlm.nih.gov/19633950/
3Study type: Preclinical (animal / in vitro) study

Glazova NY, Manchenko DM, Volodina MA, Merchieva SA, Andreeva LA, Kudrin VS, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021;86:102114. PMID: 33418449. doi:10.1016/j.npep.2020.102114

Findings: The results demonstrate that early-life FA exposure in rat pups produces long-term disturbances in their anxiety-related behaviour, learning abilities, and brain monoamines content. Semax exerts a favourable effect on behaviour and biogenic amine system of rats exposed to the antidepressant. Thus, peptide Semax can prevent behavioural deficits caused by altered 5-HT levels during development.

https://pubmed.ncbi.nlm.nih.gov/33418449/
4Study type: Preclinical (animal / in vitro) study

Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-500. PMID: 16362768. doi:10.1007/s11064-005-8826-8

Findings: This peptide alone failed to alter the tissue and extracellular concentrations of dopamine and its metabolites. Semax injected 20 min prior D: -amphetamine dramatically enhanced the effects of the latter on the extracellular level of dopamine and on the locomotor activity of animals. Our results reveal the positive modulatory effect of Semax on the striatal serotonergic system and the ability of Semax to enhance both the striatal release of dopamine and locomotor behavior elicited by D-amphetamine.

https://pubmed.ncbi.nlm.nih.gov/16362768/

Sermorelin

1Study type: Human randomized controlled trial

Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PMID: 22869065. doi:10.1001/archneurol.2012.1970

Findings: Twenty weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults. Longer-duration treatment trials are needed to further examine the therapeutic potential of GHRH administration on brain health during normal aging and “pathological aging.”

https://pubmed.ncbi.nlm.nih.gov/22869065/
2Study type: Human randomized controlled trial

Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-90. PMID: 23689947. doi:10.1001/jamaneurol.2013.1425

Findings: Twenty weeks of GHRH administration increased GABA levels in all 3 brain regions, increased NAAG levels in the frontal cortex, and decreased MI levels in the posterior cingulate. To our knowledge, this is the first evidence that 20 weeks of somatotropic supplementation modulates inhibitory neurotransmitter and brain metabolite levels in a clinical trial, and it provides preliminary support for one possible mechanism to explain favorable GHRH effects on cognition in adults with MCI and in healthy older adults. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00257712.

https://pubmed.ncbi.nlm.nih.gov/23689947/
3Study type: Human clinical trial

Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID: 9005976. doi:10.1016/s0026-0495(97)90174-8

Findings: In healthy elderly men, nightly GHRH(1-29) injections were less effective than multiple daily doses at raising GH/IGF-I, but the authors report GHRH treatment may increase muscle strength and shifted muscle bioenergetics toward reduced anaerobic demand during exercise, supporting further work on optimized regimens.

https://pubmed.ncbi.nlm.nih.gov/9005976/
4Study type: Review

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. PMID: 18031173. doi:10.2165/00063030-199912020-00007

Findings: Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30 microg/kg bodyweight is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency.

https://pubmed.ncbi.nlm.nih.gov/18031173/

SS-31 (Elamipretide)

1Study type: Human randomized controlled trial

Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. PMID: 38602181. doi:10.1016/j.gim.2024.101138

Findings: Ten patients entered the OLE; 8 reached the week 168 visit. Elamipretide was associated with sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac function in BTHS.

https://pubmed.ncbi.nlm.nih.gov/38602181/
2Study type: Preclinical (animal / in vitro) study

Whitson JA, Martín-Pérez M, Zhang T, Gaffrey MJ, Merrihew GE, Huang E, et al. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. Geroscience. 2021;43(5):2395-2412. PMID: 34480713. doi:10.1007/s11357-021-00447-6

Findings: We also found changes in the mouse heart phosphoproteome that were associated with age, some of which were partially restored with elamipretide treatment. Parallel reaction monitoring of a subset of phosphorylation sites revealed that the unmodified peptide reporting for Myot S231 increased with age, but not its phosphorylated form and that both phosphorylated and unphosphorylated forms of the peptide covering cMyBP-C S307 increased, but that elamipretide treatment did not affect these changes. These results suggest that changes to thiol redox state and phosphorylation status are two ways in which age may affect mouse heart function, which can be restored by treatment with elamipretide.

https://pubmed.ncbi.nlm.nih.gov/34480713/
3Study type: Preclinical (animal / in vitro) study

Zhao W, Xu Z, Cao J, Fu Q, Wu Y, Zhang X, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019;16(1):230. PMID: 31747905. doi:10.1186/s12974-019-1627-9

Findings: These findings indicate that LPS-induced memory impairment can be attenuated by the mitochondrion-targeted antioxidant elamipretide. Consequently, elamipretide may have a therapeutic potential in preventing damage from the oxidative stress and neuroinflammation that contribute to perioperative neurocognitive disorders (PND), which makes mitochondria a potential target for treatment strategies for PND.

https://pubmed.ncbi.nlm.nih.gov/31747905/

TB-500 (Thymosin Beta-4)

1Study type: Preclinical study + human randomized trial

Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. PMID: 41229390. doi:10.1093/cvr/cvaf223

Findings: These findings underscore the crucial role of rhTB4 in mitigating cardiac dysfunction in an ErbB2-dependent manner. The clinical relevance of rhTB4 is demonstrated through a randomized controlled trial, emphasizing its translational potential. Further rigorous randomized studies are needed to assess the significance of early rhTB4 use post-myocardial infarction reperfusion.

https://pubmed.ncbi.nlm.nih.gov/41229390/
2Study type: Preclinical (animal / in vitro) study

Ziegler T, Bähr A, Howe A, Klett K, Husada W, Weber C, et al. Tβ4 Increases Neovascularization and Cardiac Function in Chronic Myocardial Ischemia of Normo- and Hypercholesterolemic Pigs. Mol Ther. 2018;26(7):1706-1714. PMID: 29929787. doi:10.1016/j.ymthe.2018.06.004

Findings: In pigs with chronic myocardial ischemia (on normal or high-cholesterol diets), gene-delivered thymosin beta-4 improved capillary density and collateral vessel growth and improved cardiac function, including in the hypercholesterolemic animals.

https://pubmed.ncbi.nlm.nih.gov/29929787/
3Study type: Preclinical (animal / in vitro) study

Carion TW, Ebrahim AS, Kracht D, Agrawal A, Strand E, Kaddurah O, et al. Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis. Cells. 2018;7(10). PMID: 30241380. doi:10.3390/cells7100145

Findings: Adjunct Tβ4 treatment resulted in a significant improvement compared to PBS, Tβ4, and most remarkably, ciprofloxacin, correlating with changes in mediators of inflammation and wound healing. Collectively, these data provide evidence that wound healing is an essential aspect in the development of new therapies to treat corneal infection. Use of adjunctive Tβ4 provides a more efficacious approach for bacterial keratitis by addressing both the infectious pathogen and deleterious host response.

https://pubmed.ncbi.nlm.nih.gov/30241380/
4Study type: Preclinical (animal / in vitro) study

Lee SI, Yi JK, Bae WJ, Lee S, Cha HJ, Kim EC. Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells. PLoS One. 2016;11(1):e0146708. PMID: 26789270. doi:10.1371/journal.pone.0146708

Findings: In conclusion, this study demonstrated, for the first time, that Tβ4 was down-regulated in ROS-stimulated PDLCs as well as Tβ4 activation exhibited anti-inflammatory effects and anti-osteoclastogenesis in vitro. Thus, Tβ4 activation might be a therapeutic target for inflammatory osteolytic disease, such as periodontitis.

https://pubmed.ncbi.nlm.nih.gov/26789270/

Tesamorelin

1Study type: Human randomized controlled trial

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. PMID: 18690162. doi:10.1097/QAD.0b013e32830a5058

Findings: Treatment with tesamorelin was generally well tolerated and resulted in sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose. Though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment.

https://pubmed.ncbi.nlm.nih.gov/18690162/
2Study type: Human randomized controlled trial

Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PMID: 38905488. doi:10.1097/QAD.0000000000003965

Findings: The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.

https://pubmed.ncbi.nlm.nih.gov/38905488/
3Study type: Meta-analysis

Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PMID: 41545261. doi:10.1016/j.orcp.2026.01.002

Findings: Five RCTs evaluating Tesamorelin were included in the analysis. Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.

https://pubmed.ncbi.nlm.nih.gov/41545261/
4Study type: Human randomized controlled trial

Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2):210-8. PMID: 15249570. doi:10.1001/jama.292.2.210

Findings: GHRH was well tolerated and effectively increased levels of IGF-1 in HIV-infected men with lipodystrophy. Total and regional body composition improved in response to GHRH, with increased lean mass and reduced truncal and visceral fat. Use of GHRH may potentially be a beneficial treatment strategy for this population.

https://pubmed.ncbi.nlm.nih.gov/15249570/

Thymosin Alpha 1

1Study type: Human randomized controlled trial

Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. PMID: 23327199. doi:10.1186/cc11932

Findings: A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group. The use of Tα1 therapy in combination with conventional medical therapies may be effective in improving clinical outcomes in a targeted population of severe sepsis.

https://pubmed.ncbi.nlm.nih.gov/23327199/
2Study type: Human randomized controlled trial

Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat. 2005;12(3):300-6. PMID: 15850471. doi:10.1111/j.1365-2893.2005.00633.x

Findings: All adverse drug reactions were mild and most involved the fluctuation of liver enzymes, which was most likely related to the positive immune effects caused by the response to Talpha1 treatment. Adverse event incidence was similar in the 1.6- and 0.8-mg treatment groups. In conclusion, Talpha1 at doses of 0.8 and 1.6 mg exhibits long-term efficacy against hepatitis B with a good safety profile.

https://pubmed.ncbi.nlm.nih.gov/15850471/
3Study type: Human pilot trial

Shehadeh F, Benitez G, Mylona EK, Tran QL, Tsikala-Vafea M, Atalla E, et al. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis. 2023;227(2):226-235. PMID: 36056913. doi:10.1093/infdis/jiac362

Findings: A total of 49 patients were included in this analysis. Tα1 increases CD4+ T-cell count among patients with baseline low-flow oxygen support faster than the standard of care and may have a role in the management of hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.

https://pubmed.ncbi.nlm.nih.gov/36056913/
4Study type: Review

Liaw YF. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19 Suppl 6:S73-5. PMID: 15546254. doi:10.1111/j.1440-1746.2004.03633.x

Findings: Thymalfasin (thymosin-alpha1) is an immunoregulatory agent able to enhance Th1 response. It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with thymalfasin and interferon and results are promising.

https://pubmed.ncbi.nlm.nih.gov/15546254/

VIP (Vasoactive Intestinal Peptide)

1Study type: Human randomized controlled trial

Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022;50(11):1545-1554. PMID: 36044317. doi:10.1097/CCM.0000000000005660

Findings: The primary end point did not reach statistical significance, indicating that there was no difference between Aviptadil versus placebo. However, Aviptadil improves the likelihood of survival from respiratory failure at day 60 in critical COVID-19 across all sites of care. Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment.

https://pubmed.ncbi.nlm.nih.gov/36044317/
2Study type: Human clinical trial

Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540-8. PMID: 20442436. doi:10.1164/rccm.200909-1451OC

Findings: This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders. Thus, the inhalation of neuropeptides may be developed into a new therapeutic principle for chronic inflammatory lung disorders in humans.

https://pubmed.ncbi.nlm.nih.gov/20442436/
3Study type: Human clinical study

Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32(5):1289-94. PMID: 18978135. doi:10.1183/09031936.00050008

Findings: In patients with pulmonary hypertension, inhaled aviptadil (VIP) produced a modest, short-lived pulmonary vasodilation without side effects, reduced right-ventricular workload without lowering systemic blood pressure, and tended to improve oxygenation in patients with significant lung disease.

https://pubmed.ncbi.nlm.nih.gov/18978135/

No citations match your search.

Are you 21 or older?

You must be 21 years of age or older to enter this website.